AAPL339.31-3.63 (-1.06%) ▼|ABBV288.39+5.71 (+2.02%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.31-3.63 (-1.06%) ▼|ABBV288.39+5.71 (+2.02%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
20.2 C
New York
Tuesday, October 20, 2026

Tag: medicine

newsFORsourcecompanycontentinformation1releasesmarket

Bay Area Lyme Foundation Announces National Winner of the 2025 Emerging Leader Award to Develop a Much-Needed Rapid, Low-Cost, Easy-to-Use Lyme Disease Test

Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases 
Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases

Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development

SALT LAKE CITY, June 12, 2025 /PRNewswire/ -- Rebel Medicine Inc, a clinical‑stage biotechnology company developing innovative drug delivery systems and non‑opioid pain therapeutics...

Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease

SUMMIT, N.J., June 12, 2025 /PRNewswire/ -- Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, announced today that...

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

RadioMedix Debuts Proprietary bench top ²¹²Pb Generator to Support Targeted Alpha Therapy Development

New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted alpha therapy research and development 
New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted alpha therapy research and development

CRAACO Conference Focuses on Getting More Clinical Trials Into Healthcare Systems

The Conference Forum announced the launch of the 2025 CRAACO®: Clinical Research as a Care Option event, focused on getting the option of clinical...

Karmanos Cancer Institute Continues Community Education Series in June: Understanding Lung Cancer Diagnosis and Treatment Options

The Community Conversations on Cancer seminar series, in partnership with the Detroit Public Library, allows Michigan residents to learn from researchers and physician-scientists DETROIT, June...

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

TELUS Submits Non-Binding Indication of Interest to Acquire Full Ownership of TELUS Digital

Acquisition would offer TELUS Digital shareholders liquidity at a compelling value and enhance TELUS Digital's ability to effectively respond to changing market dynamics Closer operational...

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS)...

Medical Second Opinion Market to Hit USD 19.03 Billion by 2029, Driven by Cancer and Chronic Care | Valuates Reports

BANGALORE, India, June 12, 2025 /PRNewswire/ -- Medical Second Opinion Market is Segmented by Type (Hospitals, Medical Second Opinion Providing Companies, Health Insurance Companies),...

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia...

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.

Real-world prospective data confirms improved risk stratification in multiple myeloma using SKY92 gene expression profiling

According to clinical guidelines, high-risk myeloma patients should receive intensified treatment regimens. However, heterogeneity in clinical markers and staging systems lead to various interpretations of...

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect...

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax1

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers